Clinical Trials · NCT00891553

CR9112792, a Follow-up of Study CR9108963

Phase
N/A
Recruitment status
Completed
Sponsor
GlaxoSmithKline
Enrollment
171
Start date
Mar 2009
Locations
3 sites, Denmark, Norway
Primary endpoint
Percent change in BMD, as measured by DXA, at the lumbar spine (L1-L4)
View Teriparatide compound reference